Lundbeck, a global biopharmaceutical leader focused exclusively on brain health, and EVERSANA®, a leading global provider of commercial services to the life sciences sector, have announced a strategic partnership to scale AI-powered commercialization across Lundbeck’s U.S. commercial organization.
The expanded collaboration builds on initial successful deployments and broadens Lundbeck’s integration of EVERSANA’s AI Agency platform. By leveraging agentic AI orchestration, workflow automation, and human oversight, the platform establishes an operating model designed to accelerate strategic planning, content generation, and omnichannelengagement while strictly adhering to life sciences governance and medical, legal, and regulatory (MLR) compliance.
Under the partnership, Lundbeck will scale these capabilities across multiple key commercial functions, including marketing, medical communications, market access, and media operations. The initiative directly supports Lundbeck’s “Focused Innovator” strategy and ambition to build “bionic capabilities” combining artificial intelligence with deep human domain expertise to streamline operations and enhance speed-to-market.
Executive leadership from both organizations emphasized that the alliance moves beyond isolated AI pilot programs into enterprise-level commercial execution. By embedding compliance and scientific rigor into AI workflows, the partnership aims to enhance operational agility, reduce cycle times, and ultimately deliver greater value and essential therapies to patients living with neurological and psychiatric disorders.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
